Recursion Pharmaceuticals Stock Today
| RXRX Stock | USD 8.01 1.42 21.55% |
Performance3 of 100
| Odds Of DistressLess than 19
|
Recursion Pharmaceuticals is trading at 8.01 as of the 7th of December 2024; that is 21.55 percent increase since the beginning of the trading day. The stock's open price was 6.59. Recursion Pharmaceuticals has less than a 19 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. The performance scores are derived for the period starting the 17th of January 2023 and ending today, the 7th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of April 2021 | Category Healthcare | Classification Health Care |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company has 381.9 M outstanding shares of which 64.57 M shares are at this time shorted by private and institutional investors with about 12.25 trading days to cover. More on Recursion Pharmaceuticals
Recursion Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| COO President | Tina Larson | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRecursion Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Recursion Pharmaceuticals' financial leverage. It provides some insight into what part of Recursion Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recursion Pharmaceuticals (RXRX) is traded on NASDAQ Exchange in USA. It is located in 41 South Rio Grande Street, Salt Lake City, UT, United States, 84101 and employs 500 people. Recursion Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.56 B. Recursion Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 381.9 M outstanding shares of which 64.57 M shares are at this time shorted by private and institutional investors with about 12.25 trading days to cover.
Recursion Pharmaceuticals currently holds about 515.44 M in cash with (287.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.98.
Check Recursion Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationRecursion Pharmaceuticals owns a total of 381.9 Million outstanding shares. Over half of Recursion Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Recursion Ownership Details
Recursion Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Nvidia Corp | 2024-09-30 | 7.7 M | |
| Data Collective Iv Gp, Llc | 2024-09-30 | 5.9 M | |
| Geode Capital Management, Llc | 2024-09-30 | 5.4 M | |
| Dcvc Opportunity Fund Ii Gp, Llc | 2024-09-30 | 4 M | |
| Exor Investments (uk) Llp | 2024-09-30 | 3.7 M | |
| Deerfield Management Co | 2024-09-30 | 2.3 M | |
| Ubs Asset Mgmt Americas Inc | 2024-09-30 | 2.1 M | |
| Northern Trust Corp | 2024-09-30 | 2 M | |
| Norges Bank | 2024-06-30 | 1.9 M | |
| Ark Investment Management Llc | 2024-09-30 | 32.8 M | |
| Baillie Gifford & Co Limited. | 2024-09-30 | 25.2 M |
Recursion Pharmaceuticals Historical Income Statement
Recursion Stock Against Markets
Recursion Pharmaceuticals Corporate Management
| Christopher Gibson | CEO CoFounder | Profile | |
| Kevin Leggat | Vice Accounting | Profile | |
| Janelle Gordon | Vice Operations | Profile | |
| Shafique MD | Interim Officer | Profile | |
| Nathan Hatfield | Chief Officer | Profile |
Additional Tools for Recursion Stock Analysis
When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.